OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Biotechnology

OcuTerra Therapeutics

Susannah Sinozich

David J. Tanzer

Bill Steinkrauss

The Advisory Team at OcuTerra Therapeutics provides strategic guidance and expert insights to support the development and commercialization of OTT166. Comprising experienced professionals in ophthalmology, pharmacology, and business strategy, the team advises on clinical trial design, regulatory pathways, and market entry strategies to ensure the successful treatment of diabetic eye disease.

Advisory Team

About

Team members

Other teams at OcuTerra Therapeutics

Clinical and Medical Affairs Team

Leadership Team